Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID
OBJECTIVE: To compare the efficacy and safety of long term use of ranitidine 150 mg bid, 300 mg bid and placebo in prevention of endoscopic and symptomatic relapse of reflux esophagitis in...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1997-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1997/954342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563595435573248 |
|---|---|
| author | John H Hegarty Lars Halvorsen Bouke P Hazenberg Andrzej Nowak Colin L Smith Alan B Thomson G Vantrappen Ceri J Mckenna Jane G Mills |
| author_facet | John H Hegarty Lars Halvorsen Bouke P Hazenberg Andrzej Nowak Colin L Smith Alan B Thomson G Vantrappen Ceri J Mckenna Jane G Mills |
| author_sort | John H Hegarty |
| collection | DOAJ |
| description | OBJECTIVE: To compare the efficacy and safety of long term use of ranitidine 150 mg bid, 300 mg bid and placebo in prevention of endoscopic and symptomatic relapse of reflux esophagitis in an international, double-blind, placebo controlled, parallel group study. |
| format | Article |
| id | doaj-art-d45145b5dd4a439780378a18780bac74 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1997-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-d45145b5dd4a439780378a18780bac742025-02-03T01:13:14ZengWileyCanadian Journal of Gastroenterology0835-79001997-01-01111838810.1155/1997/954342Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BIDJohn H Hegarty0Lars Halvorsen1Bouke P Hazenberg2Andrzej Nowak3Colin L Smith4Alan B Thomson5G Vantrappen6Ceri J Mckenna7Jane G Mills8St Vincent’s Hospital, Dublin, Eire, IrelandSentralsykehuset i, Rogaland, Stavangar, NorwayDrechtstedenzie-Kenhuis Refaja, Dordrecht, NetherlandsKlinika Gastroenterologii, AM, Katowice, PolandSouthampton General Hospital, Southampton, UKUniversity of Alberta, Calgary, Alberta, CanadaGasthuisberg, Leuven, BelgiumGlaxo Research and Development Limited, Greenford, UKGlaxo Research and Development Limited, Greenford, UKOBJECTIVE: To compare the efficacy and safety of long term use of ranitidine 150 mg bid, 300 mg bid and placebo in prevention of endoscopic and symptomatic relapse of reflux esophagitis in an international, double-blind, placebo controlled, parallel group study.http://dx.doi.org/10.1155/1997/954342 |
| spellingShingle | John H Hegarty Lars Halvorsen Bouke P Hazenberg Andrzej Nowak Colin L Smith Alan B Thomson G Vantrappen Ceri J Mckenna Jane G Mills Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID Canadian Journal of Gastroenterology |
| title | Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID |
| title_full | Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID |
| title_fullStr | Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID |
| title_full_unstemmed | Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID |
| title_short | Prevention of Relapse in Reflux Esophagitis: A Placebo Controlled Study of Ranitidine 150 mg BID and 300 mg BID |
| title_sort | prevention of relapse in reflux esophagitis a placebo controlled study of ranitidine 150 mg bid and 300 mg bid |
| url | http://dx.doi.org/10.1155/1997/954342 |
| work_keys_str_mv | AT johnhhegarty preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT larshalvorsen preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT boukephazenberg preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT andrzejnowak preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT colinlsmith preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT alanbthomson preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT gvantrappen preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT cerijmckenna preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid AT janegmills preventionofrelapseinrefluxesophagitisaplacebocontrolledstudyofranitidine150mgbidand300mgbid |